InvestorsHub Logo
Followers 494
Posts 32009
Boards Moderated 0
Alias Born 03/12/2014

Re: None

Thursday, 03/28/2024 11:45:14 AM

Thursday, March 28, 2024 11:45:14 AM

Post# of 96
IND filing for our SNK01 program for Parkinson's Disease, and a preliminary data readout of our SNK02 allogeneic Phase I study in solid tumors, the first and only product candidate that does not require lymphodepletion, the latter two which are anticipated in the first quarter of 2024."
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NKGN News